ReachMD

Be part of the knowledge.™

Clinical Pharmacology

751

LikeLikedUnlike

Episodes 1-15 of 234

- Yohann Loriot, MD, PhD
  Peer
- Robert J. Motzer, MD
  Peer
2
CME/CE
Principles and Practice Strategies for Immunotherapy in Genitourinary Malignancies
Principles and Practice Strategies for Immunotherapy in Genitourinary Malignancies
1.00 credits
- Linda Bernstein, Pharm.D.
  Peer
4
The Drug Report
Second Ebola Virus Treatment Approved
Second Ebola Virus Treatment Approved
- Linda Bernstein, Pharm.D.
  Peer
6
The Drug Report
Another COVID-19 Vaccine Milestone Reached
Another COVID-19 Vaccine Milestone Reached
- Edward Chu, MD
  Peer
- Michael J. Overman, MD
  Peer
5
CME/CE
Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
0.25 credits
- Linda Bernstein, Pharm.D.
  Peer
5
The Drug Report
Lawsuit Against HHS Highlights 340B Drug Pricing Dispute
Lawsuit Against HHS Highlights 340B Drug Pricing Dispute
- Linda Bernstein, Pharm.D.
  Peer
6
The Drug Report
FDA Issues EUA for Pfizer-BioNTech COVID-19 Vaccine
FDA Issues EUA for Pfizer-BioNTech COVID-19 Vaccine
- Ajay K. Gopal, MD
  Peer
0
$Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma$ $Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma$
CME/CE
Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma
Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma
0.25 credits
- Linda Bernstein, Pharm.D.
  Peer
6
The Drug Report
Exploring the Emergency Use Authorization for a Monoclonal Antibody Cocktail for COVID-19
Exploring the Emergency Use Authorization for a Monoclonal Antibody Cocktail for COVID-19
- Ruben A. Mesa, MD, FACP
  Peer
5
CME/CE
Part 1: Improving Quality of Care and Shared Decision-Making in Myelofibrosis
Part 1: Improving Quality of Care and Shared Decision-Making in Myelofibrosis
0.50 credits
- Ruben A. Mesa, MD, FACP
  Peer
4
CME/CE
Part 2: Improving Quality of Care and Shared Decision-Making in Myelofibrosis
Part 2: Improving Quality of Care and Shared Decision-Making in Myelofibrosis
0.50 credits
- Karen Reckamp, MS, MD
  Peer
- Heather Wakelee, MD
  Peer
5
CME/CE
Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era
Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era
1.00 credits
- Karen Reckamp, MS, MD
  Peer
- Heather Wakelee, MD
  Peer
7
CME/CE
Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era: A Video-based Patient Case Series
Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era: A Video-based Patient Case Series
0.50 credits
- Peter Buch, MD, FACG, AGAF, FACP
  Peer
- Douglas Drossman, MD
  Peer
2
GI Insights
How Neuromodulators Can Treat Functional GI Disorders
How Neuromodulators Can Treat Functional GI Disorders
- Keith S. Kaye, MD, MPH
  Peer
- Marin H. Kollef, MD, FACP, FCCP
  Peer
- Douglas N. Fish, PharmD
  Peer
5
CME/CE
Critical Updates in Treating Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Critical Updates in Treating Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
0.25 credits
- Abdullah Abdussalam, MD
  Peer
14
AudioAbstracts
Proactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease
Proactive vs. Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease

Loading...

Programs 1/27/21

Segment Chapters

Playlist:

Recommended